Results 211 to 220 of about 1,443,667 (357)

Pyrotinib and Nab‐Paclitaxel in HER2‐Positive Breast Cancer (PANHER Trial): A Prospective, Single‐Arm, Phase II Trial

Cancer Science, EarlyView.
In this multicenter, single‐arm, open‐label phase II trial, patients with HER2‐positive breast cancer who had previously received chemotherapy with taxanes or anthracyclines were enrolled to receive pyrotinib combined with nab‐paclitaxel, and the results demonstrated promising efficacy with an acceptable safety profile.
Huan Li, Min Yan, Zhaohui Li, Xiujie Cui, Xuening Ji, Fengqi Fang, Yuyang Zhang, Yan Wang, Xiangyu Guo, Mingxi Jing, Zhichao Gao, Hui Cao, Fangyuan Dong, Jie Wu, Cui Jiang, Yangyang Duan, Xiaorui Li, Yujun Jiang, Lei Jiang, Ying E, Yufeng Jia, Liang Zhang, Pai Peng, Tao Sun   +23 more
wiley   +1 more source

Bispecific antibody toxicities. [PDF]

CMAJ
Britto J, Mian H, Davies GA, Balitsky AK.   +3 more
europepmc   +1 more source

Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma

European Journal of Haematology, EarlyView.
ABSTRACT Objective Melphalan flufenamide (melflufen) plus dexamethasone is fully approved in Europe for patients with relapsed/refractory multiple myeloma (RRMM) with ≥ 3 prior lines of therapy. We analyzed the efficacy and safety of melflufen in the real‐world setting.
Shahrier Hossain, Clifton Mo, Sarah Patches, Houry Leblebjian, Kathryn Goodrich, Eileen Regan, Kathleen O'Neill, Kim Noonan, Paul G. Richardson, Jacob Laubach   +9 more
wiley   +1 more source

Potency-optimized CD28-activating bispecific antibody for the targeted treatment of Nectin-4 positive cancers. [PDF]

J Immunother Cancer
Kaur M, Rüger K, Chen EC, Rangaswamy US, Davison LM, Moreno Arteaga S, Smith I, Chu R, Chattopadhyay S, Rickert M, Force Aldred S, Harris KE, Trinklein ND, Clarke SC.   +13 more
europepmc   +1 more source

Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system

, 2001
Christoph Renner, Ingo Stehle, Fook Thean Lee, Cathrine Hall, Bruno Catimel, Edouard C. Nice, Angela Mountain, Angela Rigopoulos, Martin W. Brechbiel, M. Pfreundschuh, Andrew M. Scott   +10 more
openalex   +1 more source

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action [PDF]

, 2007
Zhengxing Qu, David M. Goldenberg, Thomas M. Cardillo, Victoria Shi, Hans J. Hansen, Chien‐Hsing Chang   +5 more
openalex   +1 more source

Therapeutic Strategies for Relapsed or Refractory B‐Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies

European Journal of Haematology, EarlyView.
ABSTRACT The treatment landscape for relapsed or refractory acute lymphoblastic leukemia (RR ALL) has evolved significantly with the introduction of monoclonal antibodies such as blinatumomab and inotuzumab ozogamicin. These agents have demonstrated remarkable efficacy, achieving high response rates and minimal residual disease (MRD) negativity ...
Antonella Bruzzese, Enrica Antonia Martino, Caterina Labanca, Giulio Caridà, Francesco Mendicino, Eugenio Lucia, Virginia Olivito, Noemi Puccio, Antonino Neri, Fortunato Morabito, Ernesto Vigna, Massimo Gentile   +11 more
wiley   +1 more source

Development of a bispecific antibody-drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors. [PDF]

Exp Hematol Oncol
Luo M, Wang X, Yu G, Ji J, Li L, Song F.
europepmc   +1 more source

Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct [PDF]

, 2007
Scott A. Hammond, Ralf Lutterbuese, Shannon Roff, Petra Lutterbuese, Bernd Schlereth, Elizabeth Bruckheimer, Michael S. Kinch, Steve Coats, Patrick A. Baeuerle, Peter Kufer, Peter A. Kiener   +10 more
openalex   +1 more source

Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients

European Journal of Haematology, EarlyView.
ABSTRACT Relapsed/refractory multiple myeloma (RRMM) research on the impact of +1q abnormalities in real‐world settings is limited. This study evaluated the prognostic and predictive significance of 1q gain [gain(1q)] and amplification [ampl(1q)] in 635 RRMM patients treated with daratumumab‐, elotuzumab‐, and carfilzomib‐based triplet regimens ...
Fortunato Morabito, Enrica Antonia Martino, Monica Galli, Massimo Offidani, Renato Zambello, Sara Bringhen, Nicola Giuliani, Catello Califano, Marino Brunori, Alfredo Gagliardi, Nicola Sgherza, Angela Maria Quinto, Gregorio Barilà, Angelo Belotti, Claudio Cerchione, Gloria Margiotta Casaluci, Raffaele Fontana, Velia Bongarzoni, Giuseppe Tarantini, Daniele Derudas, Francesca Patriarca, Alessandro Gozzetti, Adelina Sementa, Elisabetta Antonioli, Angela Rago, Flavia Lotti, Claudio De Magistris, Maria Teresa Petrucci, Loredana Pettine, Niccolò Bolli, Concetta Conticello, Elena Zamagni, Salvatore Palmieri, Maurizio Musso, Anna Mele, Roberta Della Pepa, Ernesto Vigna, Antonella Bruzzese, Francesca Fazio, Roberto Mina, Laura Paris, Iolanda Donatella Vincelli, Giuliana Farina, Clotilde Cangialosi, Katia Mancuso, Antonietta Pia Falcone, Giuseppe Mele, Antonello Sica, Sonia Morè, Giovanni Reddiconto, Giovanni Tripepi, Graziella D'Arrigo, Emiliano Barbieri, Micol Quaresima, Claudio Salvatore Cartia, Sara Pezzatti, Magda Marcatti, Francesca Farina, Anna Cafro, Michele Palumbo, Valeria Masoni, Virginia Valeria Ferretti, Francesco Di Raimondo, Pellegrino Musto, Antonino Neri, Silvia Mangiacavalli, Massimo Gentile   +66 more
wiley   +1 more source